All HHS Contracts — February 22, 2026

SERCO's $1.05B CMS obligation (75% of period total) with $429M outlayed signals entrenched position in eligibility support, bolstering revenue visibility.

$349M across CERUS ($185M BARDA pathogen tech) and LEIDOS ($163M NIH) with $191M outlayed and run-rates to 2028 provide predictable funding in high-priority health R&D.

$620M outlayed on $1.38B total signals strong program momentum, de-risking near-term cash flows for contractors.

Extended timelines to 2026-2028 plus SERCO's 2023 expiry introduce delays or non-renewal risks on $1.38B total.

$373M in subawards (27% of total value) across 396 subs creates dependency vulnerabilities.

Firm-fixed (SERCO) and cost-no-fee (CERUS) pricing expose to overruns without reimbursement upside.

$97M unexercised options in CERUS/SERCO could lift total value 12% to $1.45B.

$760M remaining outlays through 2028 position firms for follow-on HHS work in IT/R&D.

CERUS small disadvantaged status unlocks set-aside preferences in $282M ceiling BARDA pipeline.

$349M (25%) in biotech/health R&D to 2028 reflects BARDA/NIH commitment to pathogen tech and services.

SERCO's $1.03B dominance highlights scale needs in NAICS 541512 for Medicaid support.

{"entity"=>"SERCO INC", "reason"=>"75% value concentration with 2023 expiry risks follow-on.", "trigger"=>"recompete awards or extensions post-June 2023"}

{"entity"=>"CERUS CORPORATION", "reason"=>"$97M options + small biz status for BARDA upside.", "trigger"=>"option exercises or Q2 2026 outlay acceleration"}

{"entity"=>"Leidos Biomedical Research Inc", "reason"=>"$59M remaining outlays on 9-year NIH deal through 2028.", "trigger"=>"outlay ramp to $163M completion"}